Risen Biosciences

Risen Pharma is a China-based private clinical-stage biopharmaceutical company focused on innovative therapeutics for oncology and other serious diseases. Publicly available sources indicate the company was founded in 2015 and has built capabilities spanning small molecules and siRNA, with more recent disclosures also showing oncology biologics and targeted protein degradation programs. Its most advanced disclosed asset is JS105 (also referred to as RP903), a PI3K-alpha selective inhibitor in Phase 3 testing for PIK3CA-mutated HR-positive, HER2-negative recurrent or metastatic breast cancer. Risen has also been associated with earlier-stage oncology assets including a DKK1-targeting monoclonal antibody program and preclinical KRAS degrader and ADAR1 inhibitor programs. The company appears to operate primarily from Shanghai and Suzhou and remains privately held.